{
  "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed",
  "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 52,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a three-column layout to explain the product, the strategy, and the clinical trial pipeline.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/21",
  "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed",
  "deckJsonHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed.json",
  "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "Dato-DXd = datopotamab deruxtecan; TROP2 = trophoblast cell-surface antigen 2; ADC = antibody drug conjugate; TOPO1 = topoisomerase 1; DAR = drug to antibody ratio; CTx = chemotherapy; IO = immuno-oncology; 1L = 1st-line; NSCLC = non-small cell lung cancer; HLR = high-level results.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4a37cc79-1bb3-4b28-9308-e571c1a453ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "image",
      "text": "Diagram of Dato-DXd antibody structure",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4f0418d-0a22-4054-9bf5-5614ada4c09d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.35,
        "y": 0.35
      },
      "kind": "list",
      "text": "Potential to replace CTx as monotherapy and as backbone; Further outcomes with novel combination regimens; Assess predictive value of TROP2 biomarker",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0779bb21-029a-43bb-8142-58d3f9e65ba0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.05,
        "y": 0.64
      },
      "kind": "list",
      "text": "High-potency TOPO1 payload; Payload with short systemic half-life; Optimised DAR ~4; Tumour-selective cleavable linker; Bystander anti-tumour effect",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9763792-d937-4351-9b90-be9c046813ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.7,
        "y": 0.4
      },
      "kind": "list",
      "text": "Lung: TROPION-Lung01, 07, 08, AVANZAR; Breast: TROPION-Breast01, 02, 03",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdef5592-bd34-4955-9625-013eb0a49ba1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Best-in-class TROP2 ADC investigated in monotherapy and novel combinations",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae3f5182-76f3-44d9-8e0e-a48f934ecd1b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Dato-DXd",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b411bd2c-4285-452c-b28c-e96c6e83d9ff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "98989191-2f10-4ce5-be52-dfa7a80fd132",
      "evidence": "The slide mentions a diagram of Dato-DXd antibody structure, which could be related to a 2x2 matrix, but there is not enough information to confirm.",
      "confidence": 0.5
    },
    {
      "name": "AIDA Model",
      "slug": "aida-model",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "9a48d87e-053a-408b-ad69-dd052ff15dbc",
      "evidence": "The slide presents a product (Dato-DXd) and its features, which aligns with the AIDA model's attention and interest stages.",
      "confidence": 0.5
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 15,
      "beatId": "ba7e7aa9-525b-4e2a-a4f1-214ecf8f098d",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 25,
      "from": 15,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "b41eaf1b-437d-4b91-9988-0e6fb0f284a8",
      "evidence": "The deck presents data and results from various trials, showcasing the company's progress in oncology",
      "position": 1,
      "objective": "What are the benefits of AstraZeneca's pipeline?",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}